Thomas Holbro
Impact in
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
-
- Complement system in diseases 5
- Co-authors
- Nancy E. Hynes (6 shared papers)Magdalena Koziczak (2 shared papers)Roger R. Beerli (1 shared paper)Francisca Maurer (1 shared paper)Carlos F. Barbas (1 shared paper)Gianluca Civenni (2 shared papers)Richard M. Neve (1 shared paper)Max M. Burger (1 shared paper)
- Journals
- Frontiers in Immunology (4 papers)Oncogene (2 papers)EMBO Reports (2 papers)Journal of Cellular Biochemistry (1 paper)The Annual Review of Pharmacology and Toxicology (1 paper)
- Partner nations
- SwitzerlandUnited StatesUnited Kingdom
In The Last Decade
Thomas Holbro
17 papers receiving 2.2k citations
Thomas Holbro's Hit Papers
Peers
Comparison fields: 5 of 101
- Oncology 1.3k
- Radiology, Nuclear Medicine and Imaging 672
- Immunology and Allergy 128
- Molecular Biology 1.3k
- Cancer Research 209
Countries citing papers authored by Thomas Holbro
This map shows the geographic impact of Thomas Holbro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Holbro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Holbro more than expected).
Fields of papers citing papers by Thomas Holbro
This network shows the impact of papers produced by Thomas Holbro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Holbro. The network helps show where Thomas Holbro may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Holbro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Hit paper breakdown → | 2003 | 777 |
| 2 | 2004 | 499 | |
| 3 | 2003 | 492 | |
| 4 | 2004 | 133 | |
| 5 | 2003 | 103 | |
| 6 | 2002 | 90 | |
| 7 | 2001 | 44 | |
| 8 | 2020 | 26 | |
| 9 | 2016 | 21 | |
| 10 | 2021 | 21 | |
| 11 | 2021 | 19 | |
| 12 | 2021 | 8 | |
| 13 | 2022 | 7 | |
| 14 | 2023 | 5 | |
| 15 | 2020 | 5 | |
| 16 | 2003 | 1 | |
| 17 | 2022 | 1 |
About Thomas Holbro
Thomas Holbro is a scholar working on Immunology, Molecular Biology, Oncology, Cardiology and Cardiovascular Medicine and Epidemiology, having authored 17 papers that have together received 2.3k indexed citations. Recurring topics across this work include Complement system in diseases (5 papers), HER2/EGFR in Cancer Research (5 papers), Heart Failure Treatment and Management (4 papers), Pneumonia and Respiratory Infections (4 papers), Bacterial Infections and Vaccines (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Cardiovascular Function and Risk Factors (2 papers) and Cardiac electrophysiology and arrhythmias (1 paper). The work is most often cited by research in Oncology (1.3k citations), Radiology, Nuclear Medicine and Imaging (672 citations), Immunology and Allergy (128 citations), Molecular Biology (1.3k citations) and Cancer Research (209 citations). Thomas Holbro has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Nancy E. Hynes, Magdalena Koziczak, Roger R. Beerli, Francisca Maurer, Carlos F. Barbas, Gianluca Civenni, Richard M. Neve, Max M. Burger, Gema Alonso and Laura Lin. Their work appears in journals such as Frontiers in Immunology, Oncogene, EMBO Reports, Journal of Cellular Biochemistry and The Annual Review of Pharmacology and Toxicology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.